Nitisinone Dipharma (Nitisinone)

Nitisinone blocks the enzyme p‑hydroxyphenylpyruvate dioxygenase (HPPD) in the tyrosine catabolic pathway. This inhibition prevents the formation of harmful downstream metabolites such as fumarylacetoacetate, thereby reducing liver and kidney damage associated with hereditary tyrosinemia type I.

The specific dose of Nitisinone Dipharma is determined by the prescribing physician based on the patient’s age, weight, disease severity, and laboratory parameters. Dosage adjustments are made during treatment to achieve optimal metabolic control while minimizing adverse effects.

The safety of nitisinone in pregnancy and lactation has not been established. It is classified as a pregnancy category with unknown risk, and clinicians usually weigh potential benefits against possible fetal or infant exposure before prescribing.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

The main alternative is liver transplantation, which addresses organ damage but carries surgical risks. Nitisinone offers a pharmacologic approach that can delay or avoid transplantation by controlling metabolite buildup. Compared with dietary restriction alone, nitisinone provides more reliable metabolic control.

Nitisinone Dipharma should be stored at room temperature below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

The medication is taken orally, usually as a tablet or capsule, with or without food as directed by the prescriber. Patients should follow the exact schedule and dosage instructions provided by their healthcare professional.

Serious adverse events include significant liver enzyme elevations, neutropenia, and peripheral neuropathy. Patients should be monitored regularly for hepatic function, blood counts, and neurological symptoms, and any concerning signs should prompt immediate medical evaluation.

Individuals with known hypersensitivity to nitisinone or any component of the formulation should avoid the product. Caution is also advised for patients with severe hepatic impairment, uncontrolled infections, or those taking contraindicated medications that may interact severely.